Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does sevelamer have greater skeletal benefit than calcium carbonate in children with secondary hyperparathyroidism?

Nature Clinical Practice Nephrology volume 2, pages 130–131 (2006)Cite this article

boxed-textSalusky IB et al. (2005) Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. J Am Soc Nephrol 16: 2501–2508

Although sevelamer and calcium carbonate provide equivalent control of the biochemical and skeletal lesions of secondary hyperparathyroidism in children on dialysis, sevelamer is a safer phosphate binder

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Chertow GM et al. (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245–252

    Article  CAS  Google Scholar 

  2. National Kidney Foundation (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 (Suppl 3): S1–S201

  3. Young EW et al. (2005) Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 67: 1179–1187

    Article  CAS  Google Scholar 

  4. Block GA et al. (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516–1525

    Article  CAS  Google Scholar 

  5. Chiang SS et al. (2005) Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease. Clin Nephrol 63: 461–470

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Chloe Harman, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. a Professor in the Division of Nephrology and Blood Purification Medicine at Wakayama Medical University, Wakayama, Japan

    Tadao Akizawa

Authors
  1. Tadao Akizawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tadao Akizawa.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Akizawa, T. Does sevelamer have greater skeletal benefit than calcium carbonate in children with secondary hyperparathyroidism?. Nat Rev Nephrol 2, 130–131 (2006). https://doi.org/10.1038/ncpneph0108

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneph0108

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing